Clinical Grade Viral Vector & Plasmid DNA Manufacturing Market, By Product Type (Plasmid DNA, Viral Vector, and Non-viral Vector), By Application (Cancer, Inherited Disorders, and Viral Infections), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI282119 | Publish Date: May 2024 | No. of Pages: 168

Global Clinical Grade Viral Vector Overview

Clinical Grade Viral Vector & Plasmid DNA Manufacturing market accounted for USD 0.50 Billion in 2020 and is estimated to be USD 14.5 Billion by 2030 and is anticipated to register a CAGR of 14.5%

The promise of gene therapy to address critical medical needs has been highlighted by promising outcomes in multiple clinical studies, resulting in a surge of investment in medication research and commercialization. The use of system biology and panomics to discover the reason of a patient's sickness at the molecular level is prevalent in viral vectors and plasmid DNA synthesis, followed by the use of concentrated pharmaceuticals to treat individual patients' illnesses. Plasmid DNA is becoming increasingly important in clinical research for gene therapy and genetic vaccine applications. Good manufacturing procedure (GMP)-grade plasmid DNA is required for direct gene transfer into humans.

Global Clinical Grade Viral Vector Drivers & Restraints

Due to a rise in global cancer incidence and an increase in the geriatric population susceptible to disease, the global market is predicted to grow at a healthy pace throughout the forecast period. Furthermore, government initiatives and grants, as well as increased private company investment in viral vector and plasmid DNA manufacturing R&D, are projected to drive market expansion. However, the high cost of gene therapies, as well as the risk of mutagenesis and other barriers in gene therapy, are limiting the expansion of the viral vectors and plasmid DNA production markets. In the future, new opportunities for viral vectors and plasmid DNA manufacturing market players are projected to arise due to rising demand for synthetic genes and untapped potential in emerging markets.

Global Clinical Grade Viral Vector Segmentations & Regional Insights

Clinical Grade Viral Vector & Plasmid DNA Manufacturing market is segmented based on product type, application and region.

On the basis of Product Type, the global Clinical Grade Viral Vector & Plasmid DNA Manufacturing market is segmented into Plasmid DNA, Viral Vector, and Non-viral Vector. Based on Application form, the target market is segmented into Cancer, Inherited Disorders, and Viral Infections.

Regional Insights:

Based on the region the global Clinical Grade Viral Vector & Plasmid DNA Manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has the largest market and is expected to dominate the global market over the forecast period due to presence of key players in this region. Asia-Pacific possesses high market potential, owing to increase in awareness about vector products, and rise in viral and non-viral vector applications.

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Billion & CAGR from 2020 – 2030

Market Segmentation

By ProductType – Plasmid DNA, Viral Vector, and Non-viral Vector

By Application– Cancer, Inherited Disorders, and Viral Infections

 

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global Clinical Grade Viral Vector & Plasmid DNA Manufacturing market report based on product type, application and region.

Market Segmentation - Clinical Decision Support (CDS) Market

Clinical Grade Viral Vector & Plasmid DNA Manufacturing Market, By Region:

  • North America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
      • U.S.
      • Canada

Global Clinical Grade Viral Vector Competitive Landscape & Key Players

The key players operating in the global Clinical Grade Viral Vector & Plasmid DNA Manufacturing market includes Brammer Bio, Cobra Biologics, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, MassBiologics, SIRION Biotech, Merck KGaA Inc, Thermo Fisher Scientific and Uniqure NV. In the global clinical grade viral vector & plasmid DNA manufacturing market, advancements in the product as well as the manufacturing process, product launches, and strategic collaborations are some of the trends seen. Mergers and acquisitions, as well as new product development, have been used by key companies to improve their positions in the global clinical grade viral vector and plasmid DNA manufacturing market.

Global Clinical Grade Viral Vector Company Profile

  • Brammer Bio*
  • Cobra Biologics
  • FinVector Vision Therapies
  • Fujifilm Diosynth Biotechnologies
  • MassBiologics
  • SIRION Biotech
  • Merck KGaA Inc
  • Thermo Fisher Scientific
  • Uniqure NV

FAQs

The global Clinical Grade Viral Vector & Plasmid DNA Manufacturing market is segmented based on product type, application and region.

Due to a rise in global cancer incidence and an increase in the geriatric population susceptible to disease, the global market is predicted to grow at a healthy pace throughout the forecast period.

North America has the largest market and is expected to dominate the global market over the forecast period due to presence of key players in this region.

Some of the companies operating in the global Clinical Grade Viral Vector & Plasmid DNA Manufacturing oil market are Brammer Bio, Cobra Biologics, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, MassBiologics, SIRION Biotech, Merck KGaA Inc, Thermo Fisher Scientific and Uniqure NV.